Where do you start when developing a new medicine?

A pioneering public-private research initiative between GSK, the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute is to harness the power of ‘big data’ and genome sequencing to improve the success rate for discovering new medicines.

Source: GSK news - March 27, 2014 Category: Pharmaceuticals Source Type: news